MediciNova, Inc.
HealthcareNASDAQ:MNOV · NASDAQ Global Market
-$0.05 today
Vol 0.03M · Avg 0.04M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-28.9%
avg -21.8%
ROIC
-31.6%
avg -22.1%
ROA
-26.3%
avg -20.0%
Analysis
ROA is currently the strongest return metric at -26.3% versus its period average of -20.0%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Yuichi Iwaki | Co-Founder, President, Chief Executive Officer & Chairman | $1.01M | — | 76 | $450,000.00 | 0.91% |
Kazuko Matsuda | Senior VP, Chief Medical Officer & Director | $741,191.00 | — | 60 | $350,000.00 | 0.71% |
David H. Crean | Chief Business Officer | $120,000.00 | — | 61 | $5,000.00 | 0.01% |
Jason J. Kruger | Chief Financial Officer & Principal Financial Officer | — | — | 48 | $0.00 | <0.01% |
Insider Trading
SEC Form 4 transactions — last 12 months
No insider transactions in the last 12 months.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | N/A1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
Relmada Therapeutics, Inc.
NASDAQ:RLMD
$487.67M
Immunic, Inc.
NASDAQ:IMUX
$136.78M
Vaxart, Inc.
NASDAQ:VXRT
$135.55M
Fortress Biotech, Inc.
NASDAQ:FBIO
$92.02M
XBiotech Inc.
NASDAQ:XBIT
$71.34M
Biomea Fusion, Inc.
NASDAQ:BMEA
$69.61M
PMV Pharmaceuticals, Inc.
NASDAQ:PMVP
$59.20M
Cibus, Inc.
NASDAQ:CBUS
$55.95M
TScan Therapeutics, Inc.
NASDAQ:TCRX
$55.71M
Acrivon Therapeutics, Inc. Common Stock
ACRV
$46.70M
Who manages MNOV?
MediciNova, Inc. (MNOV) lists 4 active executives. The top listed executive is David H. Crean, Chief Business Officer.
Are MNOV insiders buying or selling?
Recent insider activity shows net buying of $51.26M.
Explore More
Continue the stock analysis
Jump to another research area for this company.